NCT00161434View on ClinicalTrials.gov

A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2003

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Herpes SimplexHIV Infections
Interventions
DRUG

valacyclovir

1 gram daily for 8 weeks

DRUG

placebo

matching placebo for 8 weeks

Trial Locations (1)

98122

Virology Research Clinic, Seattle

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

National Institutes of Health (NIH)

NIH

lead

University of Washington

OTHER

NCT00161434 - A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons | Biotech Hunter | Biotech Hunter